Krikler S H, Bain G O, Gordon P A
Am J Hematol. 1984 Aug;17(2):203-8. doi: 10.1002/ajh.2830170212.
The development of Burkitt cell leukemia (FABL3) [1] in a patient 7 years after successful treatment of Hodgkin's disease (HD) by combined modality (chemotherapy and radiotherapy) therapy is described. The B-cell nature of the leukemic blasts is shown by immunologic surface marker studies. While L3 leukemia is very rarely seen following therapy for HD, diffuse lymphoma of small noncleaved cells (LSNC)--resembling the Burkitt tumor--is more common in this setting.
本文描述了一名患者在接受联合治疗（化疗和放疗）成功治愈霍奇金病（HD）7年后发生伯基特细胞白血病（FABL3）[1]的病例。免疫表面标志物研究显示白血病原始细胞具有B细胞性质。虽然HD治疗后L3白血病非常罕见，但在这种情况下，与伯基特肿瘤相似的小无裂细胞弥漫性淋巴瘤（LSNC）更为常见。
